SEC EDGARJUL 201 min read$UTHR

ROTHBLATT MARTINE A sold $5.1M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $537.05 ($528.91–$542.43, $5.10M total) across 11 trades on 2026-07-17 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · ROTHBLATT MARTINE A

Published Jul 20, 2026, 8:32 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 20, 2026, 8:39 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$UTHR

Neutral

high confidence

Mentioned

$UTHR

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$UTHRNeutralLow

Why it matters

The disclosure provides a concrete datapoint on insider selling activity, but it does not include any new company-specific performance, guidance, or regulatory development.

Market read

Traders may monitor for follow-on insider activity, but this single 10b5-1 sale is unlikely to drive a durable repricing.

What to watch

Indirect holdings and multiple small trades can obscure intent; without changes in other insiders or company guidance, the signal is weak.

Relevance 5/10Novelty 4/10Timing: Filed 2026-07-20 after the sale executed on 2026-07-17.

Background

The article is a SEC Form 4 insider transaction disclosure for United Therapeutics, reported by CEO chairperson Martine A. Rothblatt, with the sale executed across 11 trades.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$UTHRNeutralHigh confidence

Context

United Therapeutics Form 4 shows CEO chairperson Rothblatt sold $5.10M of UTHR shares via an open-market sale under a 10b5-1 plan on 2026-07-17.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 transaction with a pre-arranged 10b5-1 plan, and the article provides no new operational, regulatory, or financial catalyst.

Market effects

Sector

Minimal. Insider sales under 10b5-1 typically do not reset sector expectations for biotech/pharma.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish fundamentals, limiting interpretive value.

Key entities

issuer
United Therapeutics Corp
Subject of the Form 4 insider transaction disclosure (UTHR).
insider
Martine A. Rothblatt
Chairperson and CEO who reported an open-market sale of shares via a 10b5-1 plan.

Read at source ← All news

SEP 11

$UTHRHigh

United Therapeutics Moves to Complete Its $2 Billion Buyback, Betting the Market Is Underpricing Its Pipeline

United Therapeutics (UTHR) announced a $477.6M accelerated share repurchase agreement with Citibank, completing its $2B buyback program. CEO Martine Rothblatt stated the move reflects confidence in the company's undervalued pipeline. The company has returned $4B to shareholders in 2.5 years.

biobuzz.io2 min

SEP 11

$UTHRHigh

United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?

United Therapeutics (UTHR) committed $477.6M to a share repurchase, part of its $2B authorization. The company has $3.8B in cash and investments, with pending FDA reviews for ralinepag and Nebulized Tyvaso. Q2 revenue declined 2% to $783.3M, with Tyvaso revenue down 4%. The buyback's impact on shareholder value depends on pipeline success and cash generation.

insidermonkey.com2 min

SEP 10

$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min

SEP 9

$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min

SEP 9

$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min

SEP 8

$UTHRHighAI 8/10

United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi

United Therapeutics (UTHR) agreed to repurchase $477.6M of its common stock through an accelerated share repurchase with Citi. The company will pay upfront and receive an initial 719,376 shares, with final count based on average daily VWAP. Settlement is expected in Q4 2026.

tradingview.com1 min